Overview

On June 18, 2026, the United States Trade Representative (USTR) launched a formal Section 301 trade investigation into Germany’s pharmaceutical pricing policies, alleging that the country’s cost‑containment measures force American patients and taxpayers to bear a disproportionate share of global pharmaceutical research and development costs [1][2][3]. The probe targets Germany’s fast‑tracked GKV‑BStabG reform package, which aims to save over €16 billion in healthcare spending by imposing deeper discounts on innovative medicines, extending price freezes, and tightening reimbursement rules [4][5]. This investigation marks a significant escalation in transatlantic pharmaceutical trade tensions, coming despite a US‑EU trade deal signed in July 2025 that capped pharmaceutical tariffs at 15% [6]. The USTR has signaled that tariffs on German pharmaceutical goods—including active pharmaceutical ingredients (APIs) and finished‑dose forms—are a possible remedy, which would fundamentally alter manufacturing economics, supply chains, and investment decisions on both sides of the Atlantic [7]. The probe also follows a pattern of U.S. pressure on European drug pricing, most recently the UK‑US trade deal that secured 25% higher prices for innovative medicines in exchange for tariff exemptions [8]. This report examines the USTR’s specific allegations, Germany’s proposed spending cuts, the impact on major U.S. pharmaceutical companies with German exposure, and the broader reshaping of transatlantic pharmaceutical trade dynamics.

USTR’s Specific Allegations

Core Allegation: Disproportionate R&D Burden

The central claim of the Section 301 investigation is that Germany’s drug pricing policies leave the United States shouldering an unfair share of global pharmaceutical research and development costs. USTR Ambassador Jamieson Greer stated on June 18, 2026: “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development” [1][2]. He further expressed concern that Germany is “fast‑tracking legislation that would further reduce its spending on innovative pharmaceuticals,” calling it “a serious step backwards at a time when our trading partners need to step up and start paying their fair share to fund innovative pharmaceutical research and development” [1][3]. HHS Secretary Robert F. Kennedy Jr. reinforced the message: “Fighting the war against disease is a shared burden across wealthy nations. The United States is calling on Germany to pay its fair share for the innovative treatments its people use” [1][2].

Allegation of “Persistent Underpayment”

The USTR alleges that Germany engages in “persistent underpayment” for innovative medicines [2][3]. The investigation specifically targets Germany’s health insurance cost‑containment measures, which the administration views as an unfair free‑ride on U.S. R&D investment [7]. The U.S. demands that high‑income countries like Germany pay a fairer share for pharmaceutical innovation, and the probe is designed to pressure Berlin into raising its effective reimbursement levels [1][2].

Specific German Practices Targeted

The investigation identifies several German policies and practices as unfair trade barriers:

• The GKV‑BStabG reform package – Germany’s advancing reforms to its reimbursement and rebate policies, including plans for variable (dynamic) compulsory rebates on patent‑protected medicines, which were later abandoned in favor of fixed reductions [4][5].
• The AMNOG system – The Act on the Reorganisation of the Pharmaceutical Market in the Statutory Health Insurance System, which governs the assessment and pricing of new drugs. Under AMNOG, the Federal Joint Committee (G‑BA) conducts a benefit assessment, and the National Association of Statutory Health Insurance Funds (GKV‑Spitzenverband) negotiates reimbursement prices. If negotiations fail, an arbitration board sets the price [7].
• Reference pricing – Germany groups drugs into therapeutic clusters and sets a fixed reference price for each cluster. If a drug’s price exceeds the reference price, patients must pay the difference out‑of‑pocket, effectively capping reimbursement [7].
• Statutory health insurance (GKV) negotiations – The GKV‑Spitzenverband’s role as the central negotiating body for Germany’s statutory health insurance funds, which the USTR argues systematically depresses prices for innovative medicines [7].
• Extension of the reimbursement price freeze to end‑2030 – The draft GKV‑BStabG law extends a freeze on reimbursement prices, preventing manufacturers from adjusting prices for inflation or new evidence [4][5].
• Binding price/volume discounts under AMNOG – The reform mandates that manufacturers offer discounts tied to sales volumes, further reducing effective prices [4][5].

The MFN Framework and Germany’s Arbitration Model

The Section 301 investigation is part of a broader U.S. drug pricing strategy under the Most Favored Nation (MFN) framework, introduced in 2025. The MFN policy ties U.S. drug prices to lower international benchmarks and projects approximately $529 billion in cumulative domestic savings over a decade [7]. Notably, Germany’s existing drug pricing arbitration structure—which already requires manufacturers to submit net pricing data from reference countries—was cited in the Council of Economic Advisers report as a model for how the MFN reporting methodology was designed [7]. This makes Germany’s current cost‑containment push particularly sensitive, as it directly impacts the reference pricing system the U.S. is seeking to leverage.

Germany’s Proposed Medicine Spending Cuts

The GKV‑BStabG Reform Package

In April 2026, Germany proposed a comprehensive overhaul of its health insurance system to curb rising healthcare costs. The draft law, known as the GKV‑Finanzstabilisierungsgesetz (GKV‑BStabG), was intended to save the German healthcare system almost €20 billion in 2027 and more than €42 billion by 2030, with pharmaceutical spending cuts contributing about €1.9 billion in the first year [4][5]. The reform was driven by a projected deficit at state insurers growing from €15.3 billion in 2027 to €40.4 billion by 2030 [1][4].

Specific Cost‑Containment Measures

The original GKV‑BStabG proposal included several measures:

• Variable (dynamic) rebate system (subsequently abandoned) – The original plan would have replaced the current fixed 7% rebate on patent‑protected medicines with a variable rate linked to overall medicine spending growth. The pharma industry group VFA argued this would make companies liable for developments they cannot control, including “economic cycles, wage trends, demographics, and prescribing patterns in the overall market” [4][5].
• Retention of fixed 7% rebate (after backtracking) – On June 15, 2026, Reuters reported that Germany was abandoning plans for variable rebates and would instead retain the current fixed 7% discount, with the size of new fixed reductions not yet disclosed [4][5]. An anonymous government source told Reuters the change was made to help drugmakers plan for the shift [4].
• Extension of reimbursement price freeze to end‑2030 – The draft law extends a freeze on reimbursement prices, preventing manufacturers from adjusting prices for inflation or new evidence [4][5].
• Binding price/volume discounts under AMNOG – The reform mandates that manufacturers offer discounts tied to sales volumes, further reducing effective prices [4][5].
• Additional rebates for innovative vaccines – The draft law also includes additional rebates for innovative vaccines [4][5].
• Higher patient co‑pays – The draft law aims to save over €16 billion by increasing patient co‑pays for prescription drugs [1].

Legislative Status and German Government Position

A vote on the GKV‑BStabG reform package, originally scheduled for the week of June 19, 2026, was postponed [2][3]. The German health ministry stated that nothing has been decided yet and could not comment on parliamentary deliberations [4][5]. German Health Minister Nina Warken (of Chancellor Friedrich Merz’s conservatives) stated on June 12, 2026, that drugmakers will not be exempt from cost‑cutting measures: “Every sector must play its part in this reform” [9][10]. She argued that Germany remains an attractive location for the pharmaceutical industry “thanks to reimbursement under the statutory health insurance scheme, and the opportunities available here for clinical trials and the development of new medicines” [9][10].

Industry Response and Investment Pullbacks

The proposed reforms triggered immediate backlash from major pharmaceutical companies:

• Eli Lilly – CEO Dave Ricks revealed that Lilly was halving its planned €2.3 billion ($2.7 billion) investment in an injectable manufacturing plant in Alzey for GLP‑1 drugs Zepbound and Mounjaro. The plant will open in 2027 but at half the intended capacity and headcount (originally 1,000 jobs, now 300 employees hired). Ricks called the reforms “a terrible signal” and said Germany “will fall to last place among European markets when it comes to supporting our industry” [1][11][12].
• Boehringer Ingelheim – The German company canceled plans to invest €900 million ($1 billion) from 2027 to 2030 to expand its infrastructure in Germany. Germany head Médard Schoenmaeckers said, “As things stand, the next innovation is currently not going to Germany” and that the company must “keep pace with developments in the USA and Asia” [11][12].
• Pfizer – CEO Albert Bourla wrote to Chancellor Friedrich Merz warning that Pfizer is reviewing its “external engagements as well as the timing, scope and future prioritization of certain planned investments in Germany” [1][4].
• AstraZeneca – The company threatened to reduce capital investments in Germany and potentially decline to launch new medicines there if the GKV‑BStabG law was enacted [2][3].

The situation mirrors a similar dispute in the UK, where Merck pulled out of a $1.3 billion project and AstraZeneca paused a $270 million investment, leading the UK to later adjust its policies in the UK‑US trade deal [1][4].

Impact on Major U.S. Pharma Companies with German Exposure

Pfizer

Pfizer has significant commercial operations in Germany and a critical partnership with German mRNA company BioNTech for the Comirnaty COVID‑19 vaccine. CEO Albert Bourla warned the German government that Pfizer is reviewing its German investments in response to the proposed reforms [1][4]. Bourla has been engaged with the Trump administration on drug pricing and secured a Most Favored Nation deal [13]. In a June 19, 2026 interview, Bourla described himself as “Greek by birth and American by choice,” emphasizing the opportunities in the U.S. [14]. Pfizer has been on a major dealmaking spree, including the nearly $10 billion acquisition of Metsera (obesity‑focused) and a $10.5 billion partnership with China’s Innovent Biologics for 12 antibody‑drug conjugates [13][15]. The company is also developing PF‑08634404, a PD‑(L)1xVEGF bispecific antibody for non‑small cell lung cancer [16]. Pfizer’s German exposure is substantial, and any tariffs on German‑manufactured products or disruption to its BioNTech partnership could materially affect its European supply chain.

Merck & Co. (MSD)

Merck (known as MSD outside the U.S. and Canada) has a major presence in Germany through its subsidiary MSD Sharp & Dohme GmbH, based in Haar near Munich. The company has manufacturing and R&D operations in Germany. Merck has partnerships with German and European firms, including a clinical collaboration with Adcendo ApS to evaluate ADCE‑T02 in combination with KEYTRUDA [17]. Merck has been investing in U.S. manufacturing reshoring, with expansions noted in the BioHealth Capital Region [18]. No specific public statements from Merck about the Section 301 probe were found, but the company’s German revenue exposure makes it vulnerable to any trade actions that could affect market access or pricing.

Johnson & Johnson

Johnson & Johnson has significant pharmaceutical, medtech, and consumer health operations in Germany. CEO Joaquin Duato credited Trump administration tax policies for enabling a $55 billion U.S. investment push, including over $1 billion for a Vision manufacturing facility in Jacksonville, Florida [19][20]. Duato stated that J&J aims to manufacture all its medicines and medical technologies in the U.S. [19]. The company’s $55 billion commitment is partly a response to tariff pressures from the Trump administration [20]. J&J also reached a Most Favored Nation deal with the administration in January 2026 [13]. While J&J has not made specific public statements about the Germany probe, its strategic pivot toward U.S. manufacturing suggests it is hedging against European pricing pressures.

AbbVie

AbbVie has significant commercial operations in Germany for key products including Skyrizi, Rinvoq, and the legacy Humira franchise. The company has pledged to invest more than $10 billion in capital in the U.S. over the next decade, including $195 million to expand API production at its North Chicago facility [21]. AbbVie committed $100 billion in R&D and capital investments over the next decade, with Skyrizi and Rinvoq replacing Humira as key growth drivers [13]. No specific public statements from AbbVie about the Section 301 probe were found, but the company’s heavy U.S. investment focus suggests it is positioning to mitigate tariff risks.

Eli Lilly

Eli Lilly is one of the most directly affected U.S. companies. As detailed above, Lilly halved its €2.3 billion German investment in Alzey in response to the GKV‑BStabG reforms [1][11][12]. CEO Dave Ricks has been vocal in criticizing the German government, calling the reforms “a terrible signal” and warning that Germany will become the least supportive country in Europe for the pharmaceutical industry [1][11]. Lilly has also committed $22.7 billion in investments across the U.S., Netherlands, and India, including a $3.5 billion biomanufacturing site in Pennsylvania for retatrutide and other weight‑loss drugs [13][22]. The company’s decision to reduce its German footprint while expanding in the U.S. illustrates the direct impact of the pricing dispute on investment patterns.

Bristol Myers Squibb

Bristol Myers Squibb has significant commercial operations in Germany and a key partnership with BioNTech on pumitamig, a PD‑(L)1xVEGF bispecific antibody for first‑line non‑small cell lung cancer [16]. BMS has committed over $15 billion to a 13‑asset pipeline partnership with China’s Hengrui Pharma [23]. The company also announced a strategic agreement with Anthropic to deploy Claude Enterprise as a shared intelligence platform across its global operations [24]. No specific public statements from BMS about the Section 301 probe were found, but its German partnership with BioNTech and its commercial presence expose it to potential trade disruptions.

Amgen

Amgen has significant commercial operations in Germany for products including Repatha and UPLIZNA. The company announced plans to invest an additional $300 million in Puerto Rico to expand its manufacturing network, part of nearly $2 billion in U.S. manufacturing commitments over the past year, driven by pressure to localize production and respond to threatened tariffs on imported medicines [25]. Amgen broke ground on a $600 million center in Los Angeles/Orange County [18]. No specific public statements from Amgen about the Germany probe were found, but its U.S. manufacturing expansion aligns with the broader industry trend of reshoring to avoid tariff exposure.

Other Relevant Companies

• Boehringer Ingelheim (German company) – Canceled €900 million in German investments and agreed to invest in U.S. production and research to be exempted from pharmaceutical tariffs [11][12].
• BioNTech (German company) – Plans to close three German sites (Idar‑Oberstein, Marburg, Tübingen) and one in Singapore by end of 2027, affecting 1,860 jobs, as it pivots from COVID‑19 vaccine manufacturing toward oncology [26]. Moderna is considering acquiring these plants [26].
• Roche (Swiss company with German operations) – Proceeding with its €600 million diagnostic production site in Penzberg, Germany, but warned that the GKV‑BStabG “introduces a new level of uncertainty regarding future investment, research, and manufacturing decisions in Germany” [27].
• Moderna (U.S. company) – Considering acquiring BioNTech’s German manufacturing plants, depending on reaching a partnership agreement with the German government [26].

Transatlantic Pharmaceutical Trade Dynamics

Trade Flows and Tariff Exposure

The U.S. and EU are each other’s largest trading partners, with transatlantic trade in goods and services worth over €1.8 trillion in 2025 [6]. The pharmaceutical sector is a significant component: Germany is the largest pharmaceutical CDMO market in Europe, with approximately 98 facilities strong in API and finished‑dose forms, HPAPIs, and sterile injectables [7]. The European pharmaceutical CDMO market is projected to grow from USD 49.06 billion in 2026 to USD 94.94 billion by 2035 [28]. If the Section 301 investigation results in tariffs on German pharmaceutical goods, the impact would be substantial. Tariffs on US‑bound German APIs and finished products would materially alter European manufacturing economics, forcing reassessment of site selection, sourcing diversification, and reshoring timelines [7]. Companies with German manufacturing exposure face a prolonged period of regulatory ambiguity affecting investment, tech‑transfer, and CMO contracting [7].

Pricing Negotiations and the UK Precedent

The U.S. is pressuring Germany to follow the UK’s lead after the UK‑US trade deal allowed 25% higher prices for innovative medicines in exchange for zero tariffs on U.S. drug imports [2][3][8]. Under the UK agreement, the National Health Service committed to paying higher prices for innovative medicines in exchange for a tariff exemption [7]. The UK Department of Health and Social Care also reduced the statutory scheme levy on branded medicines from 24.3% to 16.5%, effective July 1, 2026, linked to the trade deal [29]. Greer pointed to this arrangement as a model for Germany, signaling that tariffs could be avoided via negotiated price commitments [1][2]. Germany and other European countries are now facing pressure to change the criteria for assessing the cost‑effectiveness of innovative medicines, allowing 25% higher prices to be charged [2][3].

Supply Chain Implications

The AlixPartners’ inaugural 2026 U.S. Healthcare & Life Sciences Survey found that tariffs, rising costs, and global uncertainty are significantly disrupting pharmaceutical and medical device supply chains. Nearly 30% of life sciences respondents cited supply chain disruptions as their primary pain point, while 26% pointed to tariff uncertainty and high supply costs [30]. The report highlights that policy shifts, competitive pressures, and supply chain disruptions are major contributors to sustained margin compression, weakening the sector’s historical pricing power [30]. The Pulse of Quality in Manufacturing 2026 survey found that 56% of manufacturers report significant business impact from tariffs or geopolitical issues, and 68% have raised prices as a result [31].

Investment Patterns and Reshoring

A key factor in recent biopharma cluster development is the “reshoring” of manufacturing in the U.S. by global biopharma giants, driven by growing demand for treatments—especially obesity drugs—and the desire to avoid tariffs [18][19]. Major manufacturing expansions include AbbVie, Genentech, and Novartis in North Carolina; Lilly’s $3.5 billion biomanufacturing site in Pennsylvania; and J&J’s $55 billion U.S. investment commitment [18][19]. The investment pullbacks by Eli Lilly, Boehringer Ingelheim, and Pfizer in Germany represent a significant shift in investment patterns away from Europe and toward the U.S. and Asia [11][12]. Both companies point to unfavorable conditions in Germany, including higher discounts for health insurers, and note greater dynamism in the USA and Asia [11][12]. Boehringer also references pressure from U.S. tariff policies, which require investment in America to gain exemptions [11][12].

EU Response and WTO Implications

The Section 301 investigation comes despite the US‑EU trade deal signed in July 2025 (the Turnberry Agreement), which capped pharma tariffs at 15% [6]. The European Parliament finally approved the tariff deal on June 16, 2026, just days before the U.S. deadline of July 4, 2026 [6]. The deal includes a suspension mechanism allowing the EU to act if the U.S. fails commitments or disrupts trade, and a sunset clause ending the deal on December 31, 2029, unless renewed [6]. EU Trade Commissioner Maroš Šefčovič stated that the EU has shown it is “a reliable trading partner, while standing firm in defending the interests of European stakeholders” [6].

If the U.S. imposes tariffs on German pharmaceutical goods, the EU has multiple potential WTO claims, including violations of GATT Article I (Most‑Favored‑Nation treatment), Article II (tariff bindings), and Article XI (quantitative restrictions). The EU could also challenge the underlying basis of the investigation as an improper extraterritorial application of U.S. law regarding pricing policies. The EU has several response options available, including activating countermeasures on €93 billion of U.S. goods, suspended until August 6 [6]. Bernd Lange, head of the European Parliament’s trade committee, stated the EU should be ready to activate these countermeasures [6]. The EU is also pursuing alternative trade deals (e.g., EU‑Mercosur, EU‑India) as a strategic hedge [32].

Broader Tariff Context

The investigation occurs amid broader U.S. tariff disputes. The U.S. Supreme Court ruled in February 2026 that Trump’s wide‑ranging “liberation day” tariffs were unlawful [2][3]. A subsequent U.S. trade court ruling in May 2026 also found his across‑the‑board tariffs unlawful, though they remain in effect pending appeal [2][3]. Separately, on June 3, 2026, the Trump administration proposed new tariffs of up to 12.5% on imports from 60 economies over alleged forced labor concerns, using Section 301 [32][33][34]. The EU immediately pushed back, with the European Commission stating it “fully shares US concerns about forced labour but considers tariffs imposed on these grounds to be unjustified” [32][33][34]. The forced labor tariff proposal includes pharmaceuticals among the exceptions [33].

Timeline and Context

Key Dates

• April 2026 – Germany proposed the GKV‑BStabG reform package to overhaul its health insurance system and curb rising healthcare costs [1][4].
• June 2, 2026 – USTR announced findings in 60 separate Section 301 investigations relating to forced labor goods, proposing additional duties of 10‑12.5% on imports from those economies [33][34].
• June 4, 2026 – Eli Lilly and Boehringer Ingelheim announced they were rolling back billions in planned German investments in response to the proposed reforms [11][12].
• June 12, 2026 – German Health Minister Nina Warken confirmed drugmakers would not be exempt from cost‑cutting measures [9][10].
• June 15, 2026 – Reuters reported that Germany was abandoning plans for variable rebates, instead retaining fixed reductions [4][5].
• June 16, 2026 – European Parliament approved the US‑EU trade deal (Turnberry Agreement) [6].
• June 18, 2026 – USTR opened the Section 301 investigation into Germany’s drug pricing policies [1][2][3].
• June 19, 2026 – The investigation was publicly announced; USTR Ambassador Jamieson Greer issued a press release [1][2].
• June 25 to August 10, 2026 – Public comment period for the investigation [2][3].
• September 22, 2026 – Public hearing scheduled [1][2][3].
• No timeline given for the investigation to conclude [2][3].

Historical Context

The current dispute mirrors a similar pattern of U.S. trade pressure on foreign drug pricing policies. The U.S. previously used Section 301 and other trade mechanisms to pressure Japan in the 1980s‑1990s to open its pharmaceutical market and improve pricing for U.S. drugs. More recently, the UK‑US trade deal (2025‑2026) resulted in the UK amending its cost‑effectiveness framework to allow 25% higher prices for innovative medicines, serving as the direct model for the current pressure on Germany [2][3][8]. The long‑running argument escalated in September 2025 when Merck pulled out of a $1.3 billion project in the UK and AstraZeneca paused plans to invest around $270 million in an R&D site, leading the UK to later adjust its policies [1][4].

The MFN Framework

The Section 301 investigation is part of a broader U.S. drug pricing strategy under the Most Favored Nation (MFN) framework, introduced in 2025. The MFN policy ties U.S. drug prices to lower international benchmarks and projects approximately $529 billion in cumulative domestic savings over a decade [7]. The policy uses net‑price methodology to prevent reference countries from circumventing fair‑share contributions through confidential discounts [7]. Germany’s existing drug pricing arbitration structure, which already requires manufacturers to submit net pricing data from reference countries, was cited in the Council of Economic Advisers report as a model for how the MFN reporting methodology was designed [7]. This makes Germany’s current cost‑containment push particularly sensitive, as it directly impacts the reference pricing system the U.S. is seeking to leverage.

Conclusion

The U.S. Section 301 tariff probe into Germany’s drug pricing policies represents a significant escalation in transatlantic pharmaceutical trade tensions. The investigation targets Germany’s GKV‑BStabG reform package, which the USTR alleges constitutes “persistent underpayment” for innovative medicines and an unfair free‑ride on U.S. R&D investment. The probe has already triggered investment pullbacks by major pharmaceutical companies, including Eli Lilly halving its €2.3 billion German investment and Boehringer Ingelheim canceling €900 million in planned expansions. The potential imposition of tariffs on German pharmaceutical goods would fundamentally alter manufacturing economics, supply chains, and investment patterns, accelerating the trend of reshoring pharmaceutical production to the U.S. The UK precedent, where higher prices were committed in exchange for tariff exemptions, provides a potential model for resolution, but Germany’s fiscal pressures and political dynamics make a quick compromise uncertain. The investigation, with a public hearing scheduled for September 22, 2026, and no set conclusion timeline, creates a prolonged period of regulatory ambiguity that will continue to affect investment decisions, pricing negotiations, and transatlantic trade flows in the pharmaceutical sector.